Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Allos Therapeutics reports restricted stock grant under Nasdaq rule
June 23rd, 2006
Allos Therapeutics, Inc., (ALTH) disclosed information about a grant of restricted stock awarded to Paul L. Berns as an inducement to his entering into employment with the company, in press release form, as required by NASD Marketplace Rule 4350(i)(1)(A). As an inducement for Berns to join the company as its president and CEO, on the first date of his employment with the company, March 9, 2006, Berns was granted 300,000 shares of restricted stock of the company. The restricted stock vests over a 4-year period, with 25% of the restricted stock vesting on each of the first four anniversaries of the date of grant, subject to Berns' continued employment with the company...
Source: Biotech Law Weekly (2006-06-23)
|
